STUDY SPONSOR: Nucleix, Ltd.
STUDY TYPE: Observational
This is a prospective, single visit, multi-center, observational study aimed to collect blood and clinical data from 800 subjects enrolled to the Cases Cohort and 1200 subjects enrolled to the Control Cohort. Subjects will sign the informed consent form and eligibility will be confirmed by the study team. 40ml peripheral blood will be collected in EDTA (or other type of tube if requested by the sponsor) from each subject for the purpose of the study. In addition, general clinical information, current medical status, medical history and demographics will be collected. Cancer specific information will be collected from the Cases Cohort.
This is a single visit study which includes blood collection and collection of relevant clinical information. For subjects in the Control Cohort, the sponsor may contact the site to obtain long-term data regarding cancer diagnosis.
This study is part of the development process of the Lung EpiCheck test.
If you are interested in more information on this study, please contact us. Refer to the Nucleix Lung-RND-002 study.